Current management of hepatocellular carcinoma

Table 8 Randomized controlled trias comparing transarterial chemoembolization or transarterial embolization to other treatments

Ref.	No. of patients	1 yr survival	2 yr survival	P value
Lin et al[141] 1988
TAE (gelfoam + ivalon)	21	42%	25	NS
TAE + IV 5-FU	21	20%	20
IV 5-FU	21	13%	13
Pelletier et al[142] 1990
TACE (doxorubicin, gelfoam)	21	24%	-	NS
Conservative treatment	21	33%	-
GETCH[25] 1995
TACE (cisplatin, gelfoam)	50	62%	38	NS
Conservative treatment	46	43%	26
Bruix et al[143] 1998
TAE (gelfoam, coils)	40	70	49	NS
Conservative treatment	40	72	50
Lo et al[27] 2002
TACE (cisplatin, gelfoam)	40	57	31	0.002
Conservative treatment	39	32	11
Llovet et al[26] 2002
TACE (doxorubicin, gelfoam)	40	82	63	0.009
TAE (gelfoam)	37	75	50
Conservative treatment	35	63	27

NS: Not significant; IV: Intravenous; GETCH: Groupe d’Etude et de Traitement du Carcinome He'patocellulaire; TACE: Transarterial chemoembolization; TAE: Transarterial embolization; RCT: Randomized controlled trial; FU: Fluorouracil.